2LEBV® and 2LXFS® for Epstein-Barr Virus Infection
Study to Evaluate the Efficacy of 2LEBV® and 2LXFS® on Asthenia in Patients With an Epstein-Barr Virus Infection
- Age
- 12 and older
- Sex
- Any
- Trial phase
- Phase 4
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 88 (estimated)
- Sponsor
- Labo'Life · Industry
This trial is looking for patients aged 12 and older who experience fatigue and other related symptoms due to Epstein-Barr Virus (EBV) infection. Participants will take one capsule of the treatment each day for six months.
You may be able to join if
- I am aged 12 years or older.
- I have fatigue lasting for at least 1 month.
- I have at least two additional symptoms related to EBV.
- I have a positive test for EBV infection.
You may not be able to join if
- I have received treatment with 2LEBV® or 2LXFS® before.
- I have taken homeopathic treatments in the last 2 months.
- I am currently on immunosuppressive treatment.
- I am undergoing treatment for psychiatric disorders.
- I have severe immunodeficiency disease.
- I am pregnant or breastfeeding.
- I participated in another clinical study in the last 2 months.
- I am using recreational drugs.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your EligibilityLoading trial locations…